ZZZhuxiang Zhao

Zhuxiang Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhuxiang Zhao has a total of 142 co-authors. Here are the top co-authors by number of shared publications:

  • Nanshan Zhong

    State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    6 shared publications
  • Zhongfang Wang

    State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University

    6 shared publications
  • Tingting Cui

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University Guangzhou Medical University Guangzhou Guangdong China

    4 shared publications
  • Yujun Li

    Respiratory Department, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China

    4 shared publications
  • Cheng-Yi Hu

    Department of Infectious Diseases, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China

    3 shared publications
  • Guichang Li

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    3 shared publications

Latest Publications

  • Open Access

    Complement Hyperactivation Is Mediated by Alternative and Lectin Pathways During Early Phase of Severe Vaccination‐Omicron BA.5 Infection

    by Jinpeng Cao, Gang Yang, Tingting Cui, Jian Qin, Deyi Huang, Shiqin Jin, Xiaoyun Yang, Mingzhu Huang, Xiaoling Su, Siyi Liu, et al.

    Complement temporal activation kinetics, activation pathways, and their relationship with thromboinflammation and antibody responses in severe vaccination‐COVID‐19 remains unclear. Based on a vaccinated‐infected cohort, we analyzed complement immune responses across mild to critical COVID‐19 cases by a dynamic model. Our results showed that complement activation was earlier (7–14 days post symptom onset), more intense and lasted longer in severe and critical vaccination‐COVID‐19, mediated by alternative and lectin pathways instead of classical pathway. Moreover, complement activation in severe vaccination‐COVID‐19 was related to thromboinflammation but not to the virus‐specific antibody response. Our study elucidated the kinetics of complement activation in vaccination‐COVID‐19 infection, revealing that Bb in alternative pathway were crucial in severe vaccination‐COVID‐19. These findings indicate the optimal timing for implementing complement activation‐targeted interventions in the management of severe vaccination‐COVID‐19 and provide more potential therapeutic targets.

  • Open Access

    Integrated Proteomics and Metabolomics Reveal Multifaceted Mechanisms of Colistin Resistance in Acinetobacter baumannii

    by Ling Hao, Xiao Yang, Nadeem Ullah, Yujun Li, Shuquan Wei, Qizhi Wang, Zhuxiang Zhao, Zhike Liang

    Background: The emergence of colistin-resistant Acinetobacter baumannii, particularly extensively drug-resistant carbapenemresistant A. baumannii (XDR-CRAB), poses a critical global health threat; however, the molecular mechanisms underlying this resistance remain poorly characterized. Methods: This study utilized integrated tandem mass tag (TMT)-based proteomics and untargeted metabolomics to compare a representative drug-sensitive (DS) strain, a colistin-sensitive multidrug-resistant (MDR-CRAB) strain, and a colistin-resistant extensively drug-resistant (XDR-CRAB) isolate from a Guangzhou hospital, China, with a primary focus on the molecular features associated with resistance in the XDR isolate. Results: Proteomic analysis identified 260 differentially expressed proteins (DEPs) across these strains, with 98 strongly linked to the colistin-resistant phenotype. These DEPs were enriched in functions related to polysaccharide and sulfate transport, aromatic compound degradation, and cationic antimicrobial peptide (CAMP) resistance. Upregulation of the lipid A modification system, driven by increased expression of PmrA (4.2-fold), PmrB (2.9-fold), and PmrC (5.5-fold) in the XDR strain compared to the MDR strain, is consistent with this CAMP resistance. Metabolomic analysis identified 747 metabolites, with lipids and lipid-like molecules being the most altered class. The XDR strain exhibited reduced relative abundance of several glycerophospholipids and fatty acids/ conjugates, when compared to the MDR strain, indicating cell membrane remodeling. Pathway enrichment analysis further implicated purine, glycerophospholipid, starch/sucrose, and glutathione metabolism in colistin resistance. Conclusion: Colistin resistance in A. baumannii appears to involve a multifaceted strategy integrating lipid A modification, cell membrane remodeling, and metabolic reprogramming. This study provides a high-resolution molecular blueprint of colistin resistant A. baumannii and generates testable hypotheses to inform future diagnostic and therapeutic strategies against resistant infections.


  • Open Access

    Molecular Landscape of TP53 / RB1 Co‐Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities

    by Xuetao Li, Meifeng Ye, Xiaomei Huang, Zhong‐Yin Huang, Juan Zhu, Zipeng He, Zhuxiang Zhao, Jun Hou, Shuquan Wei

    Background: Although TP53 and RB1 co‐alterations play critical roles in promoting malignant development and progression, specific inhibitors targeting this co‐alteration are lacking. We performed a pan‐cancer analysis to characterize the biology of TP53 / RB1 co‐alterations and identify therapeutic strategies. Methods: We analyzed mutation data and copy number variation (CNV) data from 42 371 pan‐cancer samples across 26 cancer types from the cBioPortal database. Among them, 2417 tumors with TP53 / RB1 co‐alterations were used for further analysis. We characterized their epidemiology and molecular biology. Therapeutic vulnerabilities of co‐altered tumors were examined using Cancer Cell Line Encyclopedia drug screening datasets. Results: TP53 / RB1 co‐alterations occurred in 5.70% of pan‐cancer cases but exhibit striking heterogeneity across cancer types. Patients harboring co‐alterations had significantly shorter overall survival (OS) in both primary and metastatic settings and poorer response to immune checkpoint inhibitors. Co‐altered tumors displayed frequent alterations in chromatin remodeling genes ( CREBBP , ARID1A , and KMT2D ) and PI3K pathway ( PIK3CA and PTEN ), but with distinct tissue‐specific mutational patterns: EGFR mutations dominated in lung adenocarcinoma (52%), KRAS in pancreatic cancer (88%), and APC in colorectal cancer (77%). Moreover, upregulated genes in co‐altered tumors enriched in cell cycle pathways, DNA repair, and neuronal development, whereas immune/inflammatory signaling was suppressed. Critically, drug screening revealed that co‐altered tumors showed increased sensitivity to CDK, AURKA, and PI3K/mTOR inhibitors, but resistance to MAPK/ERK pathway inhibitors. Conclusions: TP53 / RB1 co‐alterations define an aggressive cancer subset with dysregulated cell cycle/chromatin pathways and reduced immunotherapy response. Targeting CDK, AURKA, or PI3K signaling offers promising therapeutic strategies.


  • Open Access

    Immune imprinting toward SARS-CoV-2 XBB: implications for vaccine strategy and variant risk assessment

    by Xiaoyun Yang, Guichang Li, Yuan Wang, Tao Song, Tingting Cui, Jingjing Luo, Siyun Chen, Junjie Cao, Jiaying Zhong, Nanshan Zhong, et al.

    The immune imprinting against SARS-CoV-2 subvariants that dynamically evolves through sequential vaccination and infection has been rarely studied. Using antigenic cartography and neutralizing antibody (NAb) profiling, we demonstrate that prototype-targeting vaccination followed by Delta/early Omicron breakthrough infections maintained dominant wild-type (WT)-focused immunity. However, XBB.1.5-adapted vaccination after BA.5 outbreaks shifted immune imprinting toward XBB.1.9.1, altering the antigenic landscape. NAb analysis revealed progressive WT-specific immunity enhancement through three-dose vaccination followed by BA.5 breakthrough infection (GMT: I-I = 35, I-I-I = 72, I-I-I-B5 = 807), followed by sharp decline after XBB reinfection (GMT: I-I-I-B5-XBB = 231), confirming XBB’s antigenic divergence. To investigate the relationship between population immune dynamics and XBB infection risk following the BA.5/BF.7 wave, we analyzed the immune status of XBB breakthrough-infected and uninfected individuals from May to June 2023 (5–7 months post-wave). Utilizing an infection model calibrated to NAb titers against XBB.1.9.1, we estimated the 50% protective NAb titer against XBB infection to be 1:12.6. Retrospective analysis revealed that 80.3% of the population fell below this threshold in mid-2023, aligning with subsequent XBB resurgence. However, only 33.8% exhibited sub-protective JN.1 titers (<12.6) by August 2024, explaining the absence of JN.1-driven endemicity. This longitudinal study maps the immune imprint transitions from WT dominance to XBB adaptation, providing critical insights into vaccine strategy optimization and emerging variant risk assessment. The work highlights how iterative immune exposures reshape population protection landscapes against evolving coronaviruses.


  • Open Access

    Differences in Non-Pathogenic Lung-Colonizing Bacteria Among Patients with Different Types of Pneumonia: A Retrospective Study

    by Cheng-Yi Hu, Shu-Fang Yao, Yan-Fang Li, Qi-Zhi Wang, Yu-Jun Li, Cheng Sun, Jun Liu, Zhu-Xiang Zhao

    The clinical impact of non-pathogenic colonizing bacteria in pneumonia remains poorly understood. This retrospective study analyzed the mutual influence of pneumonia and non-pathogenic bacterial flora in the lungs. Bronchoalveolar lavage fluid samples from 483 patients were analyzed using metagenomic next-generation sequencing, and differences in colonizing bacteria in different pneumonia types and their impact on disease prognosis were determined. Patients with bacterial pneumonia exhibited higher and lower colonization rates of Granulicatella adiacens and Streptococcus parasanguinis, respectively, than those without. Fungal pneumonia showed lower and higher colonization rates of Abiotrophia defectiva and Veillonella parvula, respectively; viral pneumonia showed higher colonization rates of Abiotrophia defectiva and Streptococcus mitis. Rothia mucilaginosa was associated with shorter duration of fever, and lower risks of sepsis and multiple organ dysfunction syndrome (MODS). Prevotella melaninogenica was associated with lower risks of sepsis and MODS. These findings suggest that select non-pathogenic bacteria might influence disease severity and also highlight the need for further investigation into microbiome-based therapeutic strategies, potentially guiding personalized pneumonia treatments.


  • Open Access

    Application of the metagenomic next-generation sequencing technology to identify the causes of pleural effusion

    by Zhiyun Yan, Cheng Sun, Wanna Tang, Weitao Cao, Jin Lv, Zhike Liang, Shuquan Wei, Weinong Zhong, Ziwen Zhao, Zhuxiang Zhao, et al.

    Background: Pleural effusion (PE), frequently encountered in clinical practice, can arise from a variety of underlying conditions. Accurate differential diagnosis of PE is crucial, as treatment and prognosis are heavily dependent on the underlying etiology. However, diagnosing the cause of PE remains challenging, relying on mycobacteriological methods that lack sensitivity and are time-consuming, or on histological examinations that require invasive biopsies. The recent advancements in metagenomic next-generation sequencing (mNGS) have shown promising applications in the diagnosis of infectious diseases. Despite this, there is limited research on the utility of mNGS as a comprehensive diagnostic tool for simultaneously identifying the causes of PE, particularly in cases of tuberculosis or malignancy.Methods: This study aimed to assess the efficacy of mNGS in detecting tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE). A total of 35 patients with PE were included, and their PE samples were analyzed using mNGS.Results: Among the participants, 8 were ultimately diagnosed with TPE, and 10 were diagnosed with MPE, with lung adenocarcinoma being the most prevalent pathological type (50%, 5/10), according to established diagnostic criteria. Additionally, 7 patients were diagnosed with non-infectious PE. However, mNGS identified only 2 cases of TPE and 8 cases of MPE. The sensitivity of mNGS for detecting Mycobacterium tuberculosis was 25% (2/8), while the specificity was 100%. For tumor detection, mNGS demonstrated a sensitivity of 80%, a specificity of 92.6%, and an AUC of 0.882.Conclusion: mNGS is effective in distinguishing MPE from non-MPE, but is not suitable for diagnosing TPE.


  • Open Access

    Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk

    by Daxiang Chen, Weihong Zhang, Bin Xiao, Banglao Xu, Xiaoyun Yang, Shidong Deng, Guichang Li, Gang Yang, Jinpeng Cao, Xinyue Mei, et al.

    Vaccination against the wild-type (WT) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus did not produce detectable levels of neutralizing antibodies (NAbs) against the BA.5 strain before it emerged. However, coronavirus disease-2019 (COVID-19) severity varied highly between unvaccinated, partially vaccinated, and fully vaccinated individuals, for unknown reasons. We assessed the severity of BA.5 infection and the risk of XBB strain reinfection and measured serum levels of NAbs against WT, BA.5, and XBB.1.9.1 SARS-CoV-2 strains at varying time points in 1,373 individuals who received zero, one, two, or three WT vaccine doses. We found that two to three WT doses significantly increased WT and BA.5 NAb levels and reduced the incidence of COVID-19-associated pneumonia upon BA.5 strain infection compared to zero to one dose. Regarding XBB reinfection, those who received two to three doses and were infected with the BA.5 variant exhibited a significantly lower reinfection risk compared to those who received zero to one dose. RNA analysis revealed that the differentially expressed genes between the two to three dose and unvaccinated groups were enriched in B cell activation, cytokine-cytokine receptor interaction, complement, and monocyte activation functions—indicating that vaccination increased the antibody response and reduced inflammation. Our results suggest that multiple antigen exposures to either matched or unmatched SARS-COV-2 variants, through vaccination or infection, may be necessary to achieve significant immune imprinting. IMPORTANCE: The administration of coronavirus disease-2019 (COVID-19) vaccines that do not perfectly match the viral strains that individuals become infected with has been found to impact the resultant illness severity—although the precise mechanism underlying this phenomenon remains unclear. We assessed viral clearance, as well as serum levels of inflammatory cytokines and neutralizing antibodies (NAbs) against wild-type, BA.5, and XBB.1.9.1 variants of the severe acute respiratory syndrome coronavirus 2 among individuals who received varying doses of such strain-mismatched vaccines. Notably, vaccination with ≥2 doses of strain-mismatched COVID-19 vaccines appeared to stimulate the production of specific NAbs during infection with new variants, as well as attenuate the inflammatory response and enhance viral clearance. Such vaccination regimens can also reduce the risk of reinfection. These findings may be important for guiding the development of future COVID-19 vaccination strategies that target both matched and mismatched viral variants.


  • Open Access

    Association between computed tomography-quantified respiratory muscles and chronic obstructive pulmonary disease: a retrospective study

    by Ke Wang, Fan Wu, Hua He, Chengyi Hu, Xiaobang Chen, Jinglong Chen, Weitao Cao, Jun Liu, Jun Zhao, Ziwen Zhao, et al.

    This study examined the association between chest muscles and chronic obstructive pulmonary disease (COPD) and the relationship between chest muscle areas and acute exacerbations of COPD (AECOPD). There were 168 subjects in the non-COPD group and 101 patients in the COPD group. The respiratory and accessory respiratory muscle areas were obtained using 3D Slicer software to analysis the imaging of computed tomography (CT). Univariate and multivariate Poisson regressions were used to analyze the number of AECOPD cases during the preceding year. The cutoff value was obtained using a receiver operating characteristic (ROC) curve. We scanned 6342 subjects records, 269 of which were included in this study. We then measured the following muscle areas (non-COPD group vs. COPD group): pectoralis major (19.06 ± 5.36 cm2 vs. 13.25 ± 3.71 cm2, P < 0.001), pectoralis minor (6.81 ± 2.03 cm2 vs. 5.95 ± 1.81 cm2, P = 0.001), diaphragmatic dome (1.39 ± 0.97 cm2 vs. 0.85 ± 0.72 cm2, P = 0.011), musculus serratus anterior (28.03 ± 14.95 cm2 vs.16.76 ± 12.69 cm2, P < 0.001), intercostal muscle (12.36 ± 6.64 cm2 vs. 7.15 ± 5.6 cm2, P < 0.001), pectoralis subcutaneous fat (25.91 ± 13.23 cm2 vs. 18.79 ± 10.81 cm2, P < 0.001), paravertebral muscle (14.8 ± 4.35 cm2 vs. 13.33 ± 4.27 cm2, P = 0.007), and paravertebral subcutaneous fat (12.57 ± 5.09 cm2 vs. 10.14 ± 6.94 cm2, P = 0.001). The areas under the ROC curve for the pectoralis major, intercostal, and the musculus serratus anterior muscle areas were 81.56%, 73.28%, and 71.56%, respectively. Pectoralis major area was negatively associated with the number of AECOPD during the preceding year after adjustment (relative risk, 0.936; 95% confidence interval, 0.879–0.996; P = 0.037). The pectoralis major muscle area was negative associated with COPD. Moreover, there was a negative correlation between the number of AECOPD during the preceding year and the pectoralis major area.


  • Open Access

    Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting

    by Tingting Cui, Xiaoling Su, Jing Sun, Siyi Liu, Mingzhu Huang, Weidong Li, Chengna Luo, Li Cheng, Rui Wei, Tao Song, et al.


  • Open Access

    Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19

    by Cheng-Yi Hu, Wen-Shuai Cui, Yi Lei, Yu-Wen Tang, Yan-Yan Zhang, Qi-Min Su, Fang Peng, Yun-Fei Zeng, Jia-Lin Song, Cheng-Na Luo, et al.

    Purpose: To compare the effectiveness of azvudine and nirmatrelvir/ritonavir for the treatment of coronavirus disease (COVID-19). Patients and Methods: We conducted a retrospective analysis of data from 576 patients with COVID-19, comprising 195 patients without antiviral therapy, 226 patients treated with azvudine, 114 patients treated with nirmatrelvir/ritonavir, and 41 patients were treated with azvudine and nirmatrelvir/ritonavir concurrently. We compared their symptoms, mortality rates, and the length and cost of hospitalization. Results: The incidence of symptoms was similar in patients treated with azvudine and in those treated with nirmatrelvir/ritonavir. However, among patients experiencing weakness, the duration of weakness was significantly shorter in the azvudine group than in the nirmatrelvir/ritonavir group (P=0.029). Mortality did not differ significantly between the azvudine group and the nirmatrelvir/ritonavir group (18.14% vs.10.53%, P=0.068). Among “severe patients”, the mortality rate was markedly lower in patients treated with nirmatrelvir/ritonavir than in patients treated with azvudine (16.92% vs.32.17%, P=0.026). In patients with hepatic insufficiency, those treated with nirmatrelvir/ritonavir had substantially lower mortality than those treated with azvudine (15.09% vs.34.25%, P=0.016). In addition, patients treated with nirmatrelvir/ritonavir had longer hospital stays (P=0.002) and higher hospital costs (P< 0.001) than those receiving azvudine. Compared with patients treated with nirmatrelvir/ritonavir or azvudine alone, patients taking nirmatrelvir/ritonavir and azvudine concurrently had no significant improvement in survival (P> 0.05), length of stay (P> 0.05), or hospital costs (P> 0.05). Conclusion: Azvudine is recommended for patients with non-severe COVID-19 with weakness. Nirmatrelvir/ritonavir is recommended for patients with severe COVID-19, to reduce mortality, and it could be the best choice for patients with hepatic insufficiency. The concurrent use of nirmatrelvir/ritonavir and azvudine in patients with COVID-19 could be not recommended.